Mirum Pharmaceuticals, Inc.
MIRM · Nasdaq · United States
Share price · MIRM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MIRM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+11.4%
- 18 Sep 2026-7.1%
Nothing announced by MIRM that day or the session before.
- 6 Aug 2026-11.0%
- 30 Jun 2026-4.8%
Nothing announced by MIRM that day or the session before.
- 4 May 2026+9.6%
- 26 Feb 2026-15.1%
- 9 Jan 2026+6.1%
Nothing announced by MIRM that day or the session before.
- 19 Dec 2025+10.6%
- 17 Dec 2025+2.9%
Nothing announced by MIRM that day or the session before.
- 16 Dec 2025+4.6%
Nothing announced by MIRM that day or the session before.
Share of unusual movement by asset
For each asset, the share of MIRM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
maralixibat (Livmarli)events and moves
| 2 | shown from 8 days |
volixibatevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 31% |
| Sessions with no dated event | — | 67% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
maralixibat(Livmarli) | Approved | Ileal bile acid transporter (IBAT)Small molecule | Alagille Syndrome |
| Phase 2 | Ileal bile acid transporter (IBAT)Small molecule | Primary Sclerosing CholangitisCholestatic Liver Disease Primary Biliary Cholangitis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2029 (1)
January 2029 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $186M | $108M | $243M+ $131M short-term inv. | $41M-$4.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $176M | $91M | $331M+ $108M short-term inv. | $67M-$44M operating cash flow | report ↗ |
| 2026-Q1 | $160M | $98M | $325M+ $61M short-term inv. | $790M-$229M operating cash flow | report ↗ |
| 2025-Q3 | $133M | $43M | $282M+ $94M short-term inv. | —$40M operating cash flow | report ↗ |
| 2025-Q2 | $128M | $46M | $228M+ $76M short-term inv. | $5.9M$12M operating cash flow | report ↗ |
| 2025-Q1 | $112M | $46M | $212M+ $66M short-term inv. | $15M-$2.0M operating cash flow | report ↗ |
| 2024-Q3 | $90M | $32M | $223M+ $61M short-term inv. | $14M$4.0M operating cash flow | report ↗ |
| 2024-Q2 | $78M | $33M | $233M+ $45M short-term inv. | $25M-$3.8M operating cash flow | report ↗ |
| 2024-Q1 | $69M | $32M | $303M | $25M$15M operating cash flow | report ↗ |
| 2023-Q3 | $48M | $26M | $303M+ $3.0M short-term inv. | $24M-$18M operating cash flow | report ↗ |
| 2023-Q2 | $38M | $22M | $297M+ $33M short-term inv. | $74M-$2.3M operating cash flow | report ↗ |
| 2023-Q1 | $32M | $24M | $49M+ $83M short-term inv. | $30M-$34M operating cash flow | report ↗ |
| 2022-Q3 | $19M | $26M | $36M+ $150M short-term inv. | $36M-$26M operating cash flow | report ↗ |
| 2022-Q2 | $17M | $25M | $55M+ $70M short-term inv. | $27M-$20M operating cash flow | report ↗ |
| 2022-Q1 | $13M | $24M | $46M+ $94M short-term inv. | $37M-$40M operating cash flow | report ↗ |
| 2021-Q3 | $5.0M | $30M | $56M+ $134M short-term inv. | $47M-$34M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $521M | $186M | $297M+ $87M short-term inv. | $5.8M$56M operating cash flow | report ↗ |
Mirum Pharmaceuticals reported FY2025 revenue of $521.31M, up 54.7% YoY, with R&D spend of $186.18M, up 32.4% YoY. Cash and equivalents were $296.68M, and the company reported a net loss of $23.36M, with a quarterly net burn of $23.36M.
Business highlights include the February 2025 FDA approval of Ctexli for adults with cerebrotendinous xanthomatosis. The company expects topline data from the EXPAND Phase 3 study in Q4 2026 and from the volixibat VISTAS Phase 2b study in Q2 2026, with VANTAGE enrollment expected to complete in H2 2026. After completing the Bluejay Therapeutics acquisition on January 23, 2026, brelovitug is advancing in the AZURE program, with AZURE-1 and -4 topline results expected in H2 2026, while the MRM-3379 BLOOM Phase 2 study expects data in 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $337M | $141M | $223M+ $58M short-term inv. | $22M$10M operating cash flow | report ↗ |
| 2023-FY | $186M | $103M | $286M+ $0 short-term inv. | $41M-$71M operating cash flow | report ↗ |
| 2022-FY | $77M | $107M | $28M+ $124M short-term inv. | $34M-$120M operating cash flow | report ↗ |
| 2021-FY | $19M | $131M | $31M+ $125M short-term inv. | $21M-$133M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($9.0M), 63 sales ($45.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Ramasastry Saira · director | Option exercise | 2,000 | $28.97 | $58K | Form 4 |
| 2026-11-16 | Ramasastry Saira · director | Open-market sale | 2,000 | $92.28 | $185K | Form 4 |
| 2026-11-16 | Ramasastry Saira · director | Option exercise (derivative) | 2,000 | — | — | Form 4 |
| 2026-11-11 | Brege Laura · director | Option exercise | 14,167 | $16.71 | $237K | Form 4 |
| 2026-11-11 | Brege Laura · director | Open-market sale | 10,907 | $94.05 | $1.0M | Form 4 |
| 2026-11-11 | Brege Laura · director | Open-market sale | 3,260 | $94.74 | $309K | Form 4 |
| 2026-11-11 | Brege Laura · director | Option exercise (derivative) | 14,167 | — | — | Form 4 |
| 2026-11-04 | Peetz Christopher · director, CHIEF EXECUTIVE OFFICER | Option exercise | 20,000 | $2.94 | $59K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 309 reporting institutions held 68.2M shares ($6.1B, 104.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7,679,684 | $709.4M |
| 2 | JANUS HENDERSON GROUP PLC | 6,945,813 | $641.8M |
| 3 | BlackRock, Inc. | 3,846,530 | $355.3M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,414,776 | $223.1M |
| 5 | FMR LLC | 1,965,375 | $181.6M |
| 6 | STATE STREET CORP | 1,944,281 | $179.6M |
| 7 | BVF INC/IL | 1,584,727 | $146.4M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,432,083 | $132.3M |
| 9 | EVENTIDE ASSET MANAGEMENT, LLC | 1,408,871 | $130.1M |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 1,334,809 | $123.3M |
| 11 | NOVO HOLDINGS A/S | 1,325,000 | $122.4M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1,260,003 | $116.4M |
| 13 | TANG CAPITAL MANAGEMENT LLC | 1,236,027 | $114.2M |
| 14 | TCG Crossover Management, LLC | 1,062,049 | $98.1M |
| 15 | CITADEL ADVISORS LLC | 1,052,048 | $97.2M |